Glaukos (NYSE:GKOS) Given New $153.00 Price Target at Stifel Nicolaus

Glaukos (NYSE:GKOS) had its target price lifted by equities researchers at Stifel Nicolaus from $145.00 to $153.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 12.50% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Piper Sandler set a $140.00 target price on Glaukos in a research note on Thursday, October 17th. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. BTIG Research raised their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a report on Monday. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $136.18.

Glaukos Price Performance

GKOS opened at $136.00 on Monday. The firm has a 50-day moving average price of $134.52 and a 200-day moving average price of $125.35. Glaukos has a twelve month low of $59.58 and a twelve month high of $146.86. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $7.50 billion, a price-to-earnings ratio of -45.03 and a beta of 1.03.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos’s revenue was up 23.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.50) EPS. Equities analysts expect that Glaukos will post -1.91 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Glaukos

Several hedge funds have recently added to or reduced their stakes in GKOS. HighTower Advisors LLC increased its holdings in shares of Glaukos by 3.3% in the third quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 103 shares during the period. EFG Asset Management North America Corp. boosted its stake in shares of Glaukos by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock valued at $3,216,000 after purchasing an additional 128 shares during the period. Values First Advisors Inc. bought a new position in shares of Glaukos in the third quarter worth approximately $25,000. New York State Teachers Retirement System increased its stake in shares of Glaukos by 0.4% in the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock worth $6,272,000 after buying an additional 200 shares during the period. Finally, KBC Group NV raised its holdings in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.